

Latent Tuberculosis Checklist

Formulary: Isoniazid (INH), Rifampin, and Vitamin B6 will be available. 3 month Isoniazid and Rifapentine are not covered. See guidelines at <https://www.cdc.gov/tb/topic/treatment/ltbi.htm>.

Pyridoxine (vitamin B6), 25–50 mg/day, is recommended with INH to all persons at risk of neuropathy (e.g., pregnant women; breastfeeding infants; persons with HIV; patients with diabetes, alcoholism, malnutrition, or chronic renal failure; patients with advanced age; or contact program for certain requests).

| Demographics | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| First Name: | | Last Name: | | Date of Birth: |
| Street Address: | | City: | State: | Zip Code: Phone Number: |
| Race: <input type="checkbox"/> American Indian <input type="checkbox"/> Asian <input type="checkbox"/> Black/African American <input type="checkbox"/> Native Hawaiian/Pacific Islander | | <input type="checkbox"/> White <input type="checkbox"/> Refused | | Ethnicity: <input type="checkbox"/> Hispanic or Latino <input type="checkbox"/> Not Hispanic or Latino <input type="checkbox"/> Refused |
| Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female | | Pregnancy Status: <input type="checkbox"/> Pregnant <input type="checkbox"/> Not Pregnant <input type="checkbox"/> N/A | | Country of Birth: |
| Drug Allergies: <input type="checkbox"/> Yes <input type="checkbox"/> No Specify: | | Language: <input type="checkbox"/> English <input type="checkbox"/> Spanish <input type="checkbox"/> Other | | |
| Current Prescriptions/ Non-Prescription Drugs: <input type="checkbox"/> Yes <input type="checkbox"/> No List: | | Insurance: <input type="checkbox"/> Pharmaceutical Insurance Coverage <input type="checkbox"/> Underinsured (no pharmacy coverage) <input type="checkbox"/> Health Savings Account (HSA) | | |

| Testing Information | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|---------------------------------------------------------------------------------------------------------------|
| Tuberculin Skin Test (TST): <input type="checkbox"/> Positive <input type="checkbox"/> Negative <input type="checkbox"/> Not Performed <input type="checkbox"/> Documented Prior Positive | | Date Test Performed: Induration in mm: |
| IGRA: <input type="checkbox"/> Positive <input type="checkbox"/> Negative <input type="checkbox"/> Not Performed <input type="checkbox"/> Documented Prior Positive | | Date Test Performed: Test Value: |
| Chest X-ray: <input type="checkbox"/> Normal <input type="checkbox"/> Abnormal, but not consistent with active TB <input type="checkbox"/> Abnormal, consistent with active TB If yes, has active TB been ruled out? <input type="checkbox"/> Yes <input type="checkbox"/> No | | To prevent drug-resistant TB, LTBI treatment must not be started until active TB disease is ruled out. |

The standard of care requires CXR's to be performed within 6 months of treatment initiation and within 3 months for high risk patients such as young children, a contact to an Active TB case, new convertor, immunocompromised, prior abnormal CXR or other risk factors.

- If patient has insurance or Medicaid, please bill that entity. DHHS will not be paying for LTBI medication for patients that have insurance or Medicaid.
- Only 3 month supply (duration) provided per medication order.

| | | | | |
|-----------------|------------|----------------|-----------|---------------|
| First Name: | Last Name: | Date of Birth: | | |
| Street Address: | City: | State: | Zip Code: | Phone Number: |

| Pharmacy Information | |
|----------------------|------------------------------------------------|
| Pharmacy Name: | Date Sent to Pharmacy (DHHS staff to fill in): |
| Pharmacy Address: | |
| Pharmacy Fax: | |

| Medication Request | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|-------------------------------------------|---------------------------------------------------|
| Month # Treatment: | | | |
| Medication | Dose/mg | Frequency | Duration |
| Isoniazid | | | |
| B6* | | | |
| Rifampin | | | |
| Weight: <input type="checkbox"/> lb <input type="checkbox"/> kg | Weight required for patients that are being dosed at less than the maximum per CDC guidelines. | | |
| *The CDC treatment guidelines state Vitamin B6 is clinically indicated while taking INH to prevent peripheral neuropathy in some patients. | | | |
| <input type="checkbox"/> Diabetes | <input type="checkbox"/> Malnutrition | <input type="checkbox"/> Seizure Disorder | <input type="checkbox"/> Renal Failure/Alcoholism |
| <input type="checkbox"/> Pregnancy | <input type="checkbox"/> Breastfeeding | <input type="checkbox"/> HIV | |
| Provider Name/Credentials: | | | |
| Provider Address: | | Provider Phone Number: | |
| Provider Signature: | | | |
| Date Latent Tuberculosis Infection Checklist Filled Out: | | | |

Prescribing provider will monitor the patient for adverse drug effects, signs/symptoms of active TB and adherence.

Questions:

Nebraska TB Program Manager Phone: 402-471-6441

Nebraska Hepatitis Coordinator/TB Backup Phone: 402-471-8252

Nebraska TB Program Fax: 402-742-8359